BUSINESS
    Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
    By Hayate Horiguchi October 2, 2026
    Gilead Sciences aims to sustain its growth trajectory in Japan over the medium to long term, with new CAR-T therapy Tecartus (brexucabtagene autoleucel) and label expansions for breast cancer drug Trodelvy (sacituzumab govitecan) expected to…

    LATEST

    US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
    October 2, 2026
    The US government has narrowed the scope of a Medicare drug pricing model tied to its most-favored-nation (MFN) policy, excluding orphan-only drugs and certain other products from price reductions under the final framework and sharply…
    CSL Behring Japan Names Edward Wright as New Chief
    October 2, 2026
    CSL Behring’s Japan arm said on October 1 that Edward Wright will become president and representative director effective October 19, succeeding Izumi Yoshida, who stepped down on September 30.Wright most recently served as general manager…
    60% of EFPIA Firms Could Cut Japan Trial Investments without Policy Reform
    October 2, 2026
    Nearly two-thirds of European drug makers could reduce clinical trial investments in Japan if anticipated policy reforms, including changes to the drug pricing system, fail to materialize, according to an EFPIA Japan survey released on…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COLUMN

    Outside the Bubble: Lunch with Pharma Delegates
    By Philip Carrigan

    The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…

    COMMENTARY

    Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
    By Shinya Sato

    The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA